IN BRIEF: Indivior completes USD100 million share buyback

Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - ...

Alliance News 4 February, 2025 | 10:41AM
Email Form Facebook Twitter LinkedIn RSS

Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Completes share buyback programme begun in July. Indivior buys back 9.4 million shares at average GBP8.25, worth GBP77.7 million, about USD100.0 million, in total. The buyback was run by Morgan Stanley & Co International PLC. Last week, Indivior promoted David Wheadon to chair, starting immediately. Wheadon joined the Indivior board in June last year. Wheadon is a medical doctor who worked for GlaxoSmithKline, now GSK PLC, and Eli Lilly & Co. Until 2019, he was senior vice president of global regulatory affairs, patient safety & quality assurance at AstraZeneca PLC.

Current stock price: 930.00 pence each, down 1.3% on Tuesday morning in London

12-month change: down 32%

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Indivior PLC Ordinary Share 935.25 GBX -0.77 -
GSK PLC 1,373.00 GBX -1.82
AstraZeneca PLC 11,152.00 GBX -1.10
Eli Lilly and Co 810.43 USD -0.08

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures